ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

NIH Cool On OIG, But the Awardees Love it, DeVita Says

October 17, 1986

FDA: Silicone Breast Implants Safe, But Not “Lifetime Device”

June 24, 2011

GlaxoSmithKline Partners With MD Anderson, Fred Hutchinson

December 14, 2012

Danish Researchers Post Long-Awaited Aranesp Results–Ever So Discreetly.

February 16, 2007

To Review Cancer Bioinformatics Grid

November 12, 2010

NCI Director Broder’s Year In Review: Avoid Politics, Stay Focused On Science

October 28, 1994